Why Did Roivant Sciences Stock Gain 9% Pre-Market Today?

2026-02-06 14:43:46

The company reported the Phase 2 clinical results for its experimental oral therapy brepocitinib, along with third-quarter financial data.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.